MedPath

Tagged News

Glenmark's Blood Cancer Drug ISB 2001 Shows 83% Response Rate in Phase 1 Multiple Myeloma Trial

Oncology
  • Glenmark Pharmaceuticals' trispecific antibody ISB 2001 demonstrated an 83% overall response rate in heavily pretreated multiple myeloma patients during Phase 1 clinical trials.
  • The study showed that 20% of the 18 patients achieved complete cancer remission, with the drug displaying a favorable safety profile and durable responses.
  • Clinical experts suggest ISB 2001 could revolutionize treatment for patients who have exhausted currently approved therapies, potentially comparing favorably with existing bispecific options.
  • The positive results led to a 4% surge in Glenmark's stock price, with the company's shares outperforming the broader pharmaceutical index.

Immunochemotherapy Shows Promise for Borderline Resectable Esophageal Cancer Conversion Surgery

Oncology
  • A retrospective study of 40 patients with borderline resectable esophageal squamous cell carcinoma demonstrated that PD-1 inhibitors combined with chemotherapy achieved a 67.5% conversion surgery rate and 57.5% R0 resection rate.
  • The immunochemotherapy approach showed significantly lower toxicity compared to conventional regimens, with only 10% grade 3-4 adverse events versus 31.9-79.4% reported with traditional protocols.
  • Patients achieving clinical downstaging after induction therapy experienced significantly better overall survival and progression-free survival outcomes compared to those without downstaging.
  • The pathological complete remission rate of 27.5% was notably higher than the 14.8-18.5% typically seen with conventional chemotherapy alone for this challenging patient population.

Aktis Oncology's First-in-Class Nectin-4 Radiopharmaceutical AKY-1189 Shows Promising Tumor Uptake Across Multiple Cancer Types

Targeted TherapyOncology
  • Aktis Oncology's AKY-1189, the industry's only Nectin-4-directed radioligand therapy, demonstrated significant tumor uptake across multiple solid tumor types in first human data from 15 evaluable patients.
  • The novel miniprotein radiopharmaceutical showed excellent uptake in ER-positive breast cancer and bladder cancer, with potential applications beyond current Nectin-4 therapy Padcev.
  • Dosimetry analysis in eight patients revealed a wide therapeutic index with transient kidney uptake and no treatment-emergent adverse events, supporting progression to formal clinical trials.
  • The company is preparing to initiate phase 1 studies in South Africa and the US in 2025, following a recent $60 million deal with Lilly and $175 million Series B financing.

AI Support Significantly Improves HER2 Scoring Accuracy in Breast Cancer Diagnosis

AIPrecision MedicineOncology
• A new study published in JCO Precision Oncology demonstrates that Ibex Medical Analytics' AI technology significantly improves pathologists' accuracy and consistency in HER2 biomarker scoring for breast cancer.
• The multi-center study showed AI-assisted pathologists achieved higher inter-observer agreement (83.7% vs 75%) and improved accuracy in identifying challenging HER2-low cases, which is critical for determining eligibility for new targeted therapies.
• The "zero-click" decision support tool demonstrated exceptional robustness across multiple labs, antibodies, scanners, and patient demographics, offering particular value in distinguishing between HER2 0 and 1+ cases.

Bristol Myers Squibb Initiates Two Phase I Trials Testing Novel Therapies for Advanced Solid Tumors and Relapsed/Refractory Lymphomas

Oncology
  • Bristol Myers Squibb has launched two Phase I clinical trials evaluating experimental therapies BMS-986408 for advanced solid tumors and BMS-986458 for relapsed/refractory non-Hodgkin lymphoma.
  • The BMS-986408 study targets patients with histologically confirmed, advanced, unresectable or metastatic solid malignancies who have exhausted existing treatment options.
  • The BMS-986458 trial focuses on patients with relapsed/refractory DLBCL and follicular lymphoma who have received at least two prior lines of therapy.
  • Both studies exclude patients with autoimmune diseases and require specific performance status criteria for enrollment.

POSITIVE Trial Demonstrates Safe Breastfeeding During Endocrine Therapy Break for HR+ Breast Cancer Patients

Oncology
  • The POSITIVE trial showed that breastfeeding is feasible for young patients with hormone receptor-positive breast cancer who conceived during a planned interruption of endocrine therapy, with a median breastfeeding duration of 4.4 months.
  • Among 196 patients who breastfed, breast cancer recurrence rates remained low at 1.1% at 12 months and 3.6% at 24 months, comparable to those who did not breastfeed.
  • The study represents the largest prospective evaluation of breastfeeding patterns in young HR-positive breast cancer survivors, supporting the incorporation of breastfeeding counseling into individualized patient care.

Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer

NCT02308085Active, Not RecruitingNot Applicable
ETOP IBCSG Partners Foundation
Posted 12/4/2014

GV20 Therapeutics Reports First Clinical Data for AI-Designed Checkpoint Inhibitor GV20-0251 in Advanced Solid Tumors

Monoclonal AntibodyOncologyAI
  • GV20 Therapeutics presented Phase 1 data for GV20-0251, marking the first clinical results for an AI-designed antibody targeting an AI-predicted immune checkpoint IGSF8.
  • The study enrolled 38 heavily pre-treated patients and demonstrated favorable safety with no dose-limiting toxicities across all dose levels from 0.5 to 20 mg/kg.
  • Two confirmed partial responses were observed in 12 evaluable metastatic cutaneous melanoma patients, with 14 of 29 patients showing stable disease including tumor shrinkage.
  • The drug showed dose-proportional pharmacokinetics with a 25.6-day half-life and full target occupancy on circulating T cells at doses ≥3 mg/kg.

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

NCT05669430RecruitingPhase 1
GV20 Therapeutics
Posted 3/23/2023

McKesson Acquires $2.49 Billion Controlling Stake in Florida Cancer Specialists to Expand Community Oncology Platform

Oncology
  • McKesson Corporation agreed to purchase a 70% controlling stake in Florida Cancer Specialists' Core Ventures for approximately $2.49 billion in cash to strengthen its oncology platform.
  • The acquisition brings Florida Cancer Specialists, with over 250 physicians and 280 advanced practice providers across nearly 100 Florida locations, into McKesson's US Oncology Network.
  • The transaction aims to advance community-based cancer care by combining operational expertise to increase access to high-quality, affordable oncology services and treatments.
  • Florida Cancer Specialists will maintain independent ownership while gaining access to McKesson's differentiated oncology care products, services, and clinical trial capabilities through Sarah Cannon Research Institute.

Daiichi Sankyo and Merck Expand Collaboration to Develop Novel DLL3-Targeting T-Cell Engager for Small Cell Lung Cancer

Oncology
• Daiichi Sankyo and Merck have expanded their existing partnership to include MK-6070, an investigational DLL3-targeting T-cell engager, with Merck receiving $170 million upfront in the agreement.
• MK-6070 targets delta-like ligand 3 (DLL3), which is highly expressed in small cell lung cancer and neuroendocrine tumors, and has received FDA Orphan Drug Designation for SCLC treatment.
• The companies plan to evaluate MK-6070 in combination with ifinatamab deruxtecan (I-DXd) in patients with small cell lung cancer, addressing an aggressive cancer with significant unmet treatment needs.

A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)

NCT04471727RecruitingPhase 1
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Posted 12/14/2020

Novel Nanoparticle Immunotherapy Shows Promise in Delaying Prostate Cancer Treatment Resistance

Oncology
  • University of Sheffield researchers have developed a new nanoparticle-based immunotherapy that significantly delays resistance to androgen deprivation therapy (ADT) in prostate cancer patients.
  • The innovative approach targets macrophages around blood vessels in prostate tumors, causing them to release interferon-beta which activates T cells to attack cancer cells.
  • This breakthrough could potentially extend the effectiveness of hormone therapy for thousands of men, addressing a critical gap as traditional immunotherapies have historically shown limited success in prostate cancer.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.